An analysis of electronic health records from over 26,000 adults with obesity and at least one autoimmune disease has shown that those taking GLP-1 medication experienced fewer cardiac events, were less likely to visit the ER, and had a lower risk of death
Due to its low bioavailability, NAC must be administered at high doses, which can disrupt hepatocyte metabolism and regenerative processes, increase the risk of adverse reactions (Ntamo et al
Conclusion The evidence supports a nuanced conclusion regarding GLP-1 agonists for obesity in non-diabetic patients: they represent a significant therapeutic advance with game-changing potential currently limited by practical implementation challenges
The concept of deliberately slowing metabolism with medication is fundamentally different from treating pathological conditions that cause hypermetabolism
In just 35 seconds, Styku captures a complete 3D model of your body using safe, non-invasive light technologyno contact, no radiation, no hassle
Signs of dehydration including reduced urine output, dark concentrated urine, dizziness on standing, dry mouth, and increased thirst should prompt urgent medical review, especially in vulnerable populations
